OncoCyte (NASDAQ:OCX) Announces Quarterly Earnings Results

OncoCyte (NASDAQ:OCX) released its quarterly earnings data on Monday. The company reported $0.48 earnings per share (EPS) for the quarter, Zacks reports. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%.

OncoCyte Price Performance

Shares of NASDAQ OCX traded down $0.07 during trading hours on Monday, reaching $3.33. 32,877 shares of the stock were exchanged, compared to its average volume of 85,103. The stock’s fifty day simple moving average is $2.68 and its 200 day simple moving average is $2.72. OncoCyte has a 52 week low of $1.92 and a 52 week high of $4.75.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on OncoCyte in a report on Monday, January 13th. They set a “sell” rating for the company.

Insider Activity at OncoCyte

In other OncoCyte news, major shareholder Patrick W. Smith purchased 90,219 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was bought at an average cost of $2.13 per share, for a total transaction of $192,166.47. Following the completion of the transaction, the insider now owns 1,773,903 shares in the company, valued at approximately $3,778,413.39. This represents a 5.36 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Andrew Arno purchased 12,500 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was bought at an average price of $2.11 per share, with a total value of $26,375.00. Following the completion of the purchase, the director now owns 81,554 shares of the company’s stock, valued at $172,078.94. This trade represents a 18.10 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 1,288,344 shares of company stock worth $2,649,051 in the last ninety days. 1.58% of the stock is owned by company insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.